Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study
T Strowitzki, T Faustmann, C Gerlinger… - European Journal of …, 2010 - Elsevier
OBJECTIVE: To investigate the efficacy and safety of oral dienogest 2mg compared with
placebo in the treatment of endometriosis-associated pelvic pain (EAPP). STUDY DESIGN: This …
placebo in the treatment of endometriosis-associated pelvic pain (EAPP). STUDY DESIGN: This …
[HTML][HTML] Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
F Petraglia, D Hornung, C Seitz, T Faustmann… - Archives of gynecology …, 2012 - Springer
Purpose To investigate the efficacy and safety of dienogest as a long-term treatment in
endometriosis, with follow-up after treatment discontinuation. The study included women with …
endometriosis, with follow-up after treatment discontinuation. The study included women with …
A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis
G Köhler, TA Faustmann, C Gerlinger, C Seitz… - International Journal of …, 2010 - Elsevier
OBJECTIVES: To compare the efficacy and safety of dienogest at doses of 1, 2, and 4mg/day
orally in the treatment of endometriosis. METHODS: An open-label, randomized, multicenter…
orally in the treatment of endometriosis. METHODS: An open-label, randomized, multicenter…
Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program
T Strowitzki, T Faustmann, C Gerlinger… - … journal of women's …, 2015 - Taylor & Francis
Background In four randomized, controlled, European trials, dienogest 2 mg once daily
demonstrated significant efficacy for lesion reduction and reduction in pain intensity in …
demonstrated significant efficacy for lesion reduction and reduction in pain intensity in …
[HTML][HTML] Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo …
C Gerlinger, U Schumacher, T Faustmann… - Health and quality of life …, 2010 - Springer
Background When comparing active treatments, a non-inferiority (or one-sided equivalence)
study design is often used. This design requires the definition of a non-inferiority margin, the …
study design is often used. This design requires the definition of a non-inferiority margin, the …
Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis
T Strowitzki, J Marr, C Gerlinger, T Faustmann… - International Journal of …, 2012 - Elsevier
OBJECTIVE: To analyze the secondary efficacy and safety outcomes from a recent trial
comparing dienogest (DNG) with leuprolide acetate (LA) in women with endometriosis. …
comparing dienogest (DNG) with leuprolide acetate (LA) in women with endometriosis. …
Female perspectives on endometriosis: findings from the uterine bleeding and pain women's research study
…, C Gerlinger, K Geppert, T Faustmann - Journal of …, 2011 - journals.sagepub.com
Purpose The symptoms of endometriosis are heterogeneous and overlap with those of other
conditions, resulting in misdiagnoses and/or delayed diagnosis and treatment. The Uterine …
conditions, resulting in misdiagnoses and/or delayed diagnosis and treatment. The Uterine …
Ovulation‐inhibiting effects of dienogest in a randomized, dose‐controlled pharmacodynamic trial of healthy women
…, I Duijkers, A Remmers, T Faustmann… - The Journal of …, 2012 - Wiley Online Library
Dienogest offers pharmacological advantages for the effective treatment of endometriosis and
for use in contraception and hormone replacement therapy. This pharmacodynamic study …
for use in contraception and hormone replacement therapy. This pharmacodynamic study …
[HTML][HTML] Real world data on symptomology and diagnostic approaches of 27,840 women living with endometriosis
…, S Moehner, C Gerlinger, M Serrani, T Faustmann - Scientific reports, 2021 - nature.com
Endometriosis is a chronic disease that requires a suitable, lifelong treatment. To our knowledge,
the Visanne Post-approval Observational Study (VIPOS) is to date the largest real-world…
the Visanne Post-approval Observational Study (VIPOS) is to date the largest real-world…
Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use
…, D Apter, S Dermout, T Faustmann… - European Journal of …, 2017 - Elsevier
Objective To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine
contraceptive system (LNG-IUS 12) for up to 5 years of use. Study design In this Phase III …
contraceptive system (LNG-IUS 12) for up to 5 years of use. Study design In this Phase III …
